Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + allogeneic immune cells
- Development stage
- Unknown
- Lead developer
- Hangzhou Converd
- Modality
- Cell Therapies, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy being developed by Hangzhou Converd Co., Ltd. for the treatment of advanced solid tumors. The regimen consists of **A01**, which is the small molecule tyrosine kinase inhibitor **apatinib**, and **IC01**, which are **allogeneic immune cells** harvested from a relative of the patient. Apatinib functions as an anti-angiogenic agent by selectively binding to and inhibiting vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking the blood supply to tumors and potentially modulating the tumor microenvironment. The allogeneic immune cells (typically cytokine-induced killer cells or similar effector cells) are intended to enhance the host's anti-tumor immune response through direct cytotoxicity and the production of immunostimulatory cytokines. This combination is currently being evaluated in Phase 1 clinical trials in China to assess safety and preliminary efficacy in patients with advanced malignancies.
- Other names
- apatinib mesylate + allogeneic immune cellsA01 and IC01A-01 and IC01A 01 and IC01
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on apatinib + allogeneic immune cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + allogeneic immune cells.